GSK press releases
Follow
GLISTEN phase III trial results show linerixibat significantly improves cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)
Late-breaking results presented at the European Association for the Study of the Liver (EASL) Congress 2025
